Table 1.
Angiogenesis inhibitors.
| Compound | Angiogenic target | Schedule/dose | References |
|---|---|---|---|
| Antibodies and specialized proteins | |||
| Bevacizumab * | VEGF-A (VEGF165) | 1–6 × 5–45 mg/kg | [78,79,80,81,82,83,84,85,86,87,88] |
| DC101 | VEGFR-2 | 7 × 30mg/kg | [89] |
| VEGF-trap | VEGF-A/B, PlGF | 4 × 25mg/kg | [90] |
| Tyrosine Kinase Inhibitors | |||
| Vatalanib | PDGFR-β, c-kit, VEGFRs | 7–14 × 50–100 mg/kg | [91,92,93,94] |
| Sunitinib | VEGFRs, PDGFRs | 1–7 × 40–45 mg/kg | [95,96] |
| Orantinib | VEGFR-2, c-kit, FGFR, PDGFR | 1–14 × 200 mg/kg | [97,98] |
| Vandetanib | VEGFR-2, EGFR | 2 × 12.5–100 mg/kg | [51,99] |
| Axitinib | PDGFR, c-kit, VEGFR-1/2/3 | 14 × 25 mg/kg | [100] |
| Imatinib | PDGFR-β, c-kit, abl, VEGFR-2 | 3 × 50 mg/kg | [101] |
| Cediranib | VEGFRs | 1–20 × 6 mg/kg | [102] |
| Sorafenib | VEGFRs, PDGFRs, Raf | 25 × 7 mg/kg | [103] |
| Others | |||
| TNP-470 | MetAP2 | 3–7 × 6.7–30 mg/kg | [104] |
| Everolimus | mTOR | 1–7 × 5–10 mg/kg | [105] |
| KR-31831 | Unknown | 21 × 50 mg/kg | [106] |
| Thalidomide | FGF-2 | 2–3 × 60–200 mg/kg | [107,108,109] |
* and other anti-VEGF antibodies.